IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: IFN-α has been used for the treatment of selected tumors, including melanoma and renal cancer, showing its best efficacy in hematological malignancies, such as hairy cell leukemia, chronic myeloid leukemia, and follicular lymphoma [10].